Silo Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $1.24M
- P/E (TTM)
- –
- Dividend yield
- –
About Silo Pharma
Pharmaceutical Preparations, SIC 2834
Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency company. In its therapeutics business, the company develops conventional drugs and psychedelic formulations targeting underserved conditions, including post-traumatic stress disorder, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases. Its product pipeline features candidates such as SPC-15, an intranasal prophylactic therapy; SP-26, a time-release ketamine implant; SPC-14 for Alzheimer’s disease; and SPU-16 for neuroinflammatory conditions like multiple sclerosis. Its digital asset treasury operations focus on acquiring and staking major cryptocurrencies such as Bitcoin, Ethereum, and Solana to generate yield. The company's customer base consists of patients suffering from psychiatric, chronic pain, and neurological disorders, as well as the broader healthcare and medical community.
The company operates in the United States and maintains intellectual property licensing arrangements with international partners across Europe. It conducts business operations without active commercial sales facilities. Silo Pharma maintains its principal executive offices in Sarasota, Florida.
Summary of the business section of Silo Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Silo Pharma, Inc.
- Headquarters
- Sarasota, FL
- Address
- 677 N. Washington Blvd 34236
- Phone
- (718) 400-9031
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Salberg& Company, P.A., Boca Raton, Florida
Stock & identifiers
- Ticker
- SILO
- Exchange
- Nasdaq
- Shares outstanding
- 2M, Aug 13, 2026
- Public float
- $5.33M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Aug 13, 2026; 1-for-15 reverse, Jun 3, 2026; 1-for-50 reverse, Nov 10, 2022; 1-for-50 reverse, Sep 15, 2022
- SEC CIK
- 1514183
- CUSIP
- 82711P300
- ISIN
- US82711P3001
- EIN
- 46-2137136
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric Weisblum | Chief Executive Officer, Director | 214,432 |
| Daniel E. Ryweck | Chief Financial Officer | 5,000 |
| Wayne Linsley | Director | – |
| Kevin Munoz | Director | – |
| Jeff Pavell | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Eric Weisblum | $521.75K | $498.54K | $101.49K | $2 | – |
| FY2024 Eric Weisblum | $630.05K | $630.05K | $88.60K | $6 | – |
| FY2023 Eric Weisblum | $569.01K | $569.01K | $62.69K | $7 | – |
| FY2022 Eric Weisblum | $352.50K | $352.50K | $15.00K | $16 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 27, 2026, we employed a total of three full-time employees and we utilize specialized consultants of which we have 3 consultants with yearly contracts and use others from time to time on an as-needed basis.”
Corporate history
Events identified from SEC filings